TL;DR: A 2026 medRxiv preprint found that pupil dilation measured inside a virtual reality (VR) headset increased as working-memory load rose in healthy adults, was reproducible 60–90 days later in 33 returnees, and was smaller under the highest load in cognitively impaired patient cohorts than in 81 healthy controls. Key Findings Forty-three healthy adults completed …
TL;DR: A 2026 study in Science Advances reported that disrupting the membrane-associated periodic skeleton (MPS), an actin-spectrin lattice beneath neuron membranes, reduced the fitted amyloid precursor protein (APP) uptake time constant in cultured mouse hippocampal neurons and increased intracellular amyloid-beta 42 under APP-overexpression conditions. The cell-culture experiments do not show that stabilizing the MPS prevents …
TL;DR: A 2026 review in Journal of Neuroinflammation proposed that Alzheimer microglial dysfunction can be understood as checkpoint collapse, where failed regulatory controls feed three interacting lipid, iron/ferroptosis, and inflammation/complement axes. Key Findings Review framework, not trial result: Alzheimer microglial evidence through April 2026 was synthesized rather than used to test a new drug or …
TL;DR: A 2026 laboratory study in ACS Omega reported that a laser-induced graphene sensor detected dopamine across a controlled range in artificial human tears, supporting a possible noninvasive biomarker-monitoring route that still needs real human tear testing. Key Findings Laser-induced graphene sensor: Researchers built a small electrochemical device on a plastic film converted into conductive …
TL;DR: A 2026 post-hoc reanalysis in Molecular Psychiatry found that women assigned davunetide in a prior 52-week progressive supranuclear palsy trial had more favorable scores on the 10-item PSP Rating Scale (PSPRS-10), daily-living measures, and several cognitive outcomes than women assigned placebo, but the subgroup result needs confirmation in a prospective trial designed to test …
TL;DR: A 2026 preprint in medRxiv reported that people living with dementia (PLwD) and carers were generally open to artificial intelligence (AI) support in structured medication reviews, but only when AI remained validated, transparent, secure, and subordinate to human clinical judgement. Key Findings 26-person qualitative sample: Researchers interviewed 12 people living with dementia and ran …
TL;DR: A 2026 Nature Communications paper introduced EmulatRx, a multi-agent AI framework that used real-world clinical data to help design target-trial-emulation workflows for acute and chronic diseases, including Alzheimer disease and Parkinson disease examples. Key Findings 20-trial evaluation: Researchers curated 20 clinical trials, with 10 acute-condition trials from MIMIC-IV and 10 chronic-disease trials from INSIGHT. …
TL;DR: A 2026 study in eNeuro used intracranial electroencephalography (EEG), a recording method for brain electrical activity, during deep brain stimulation surgery and found that Parkinson’s disease and essential tremor patients with elevated depression symptoms had weaker corticostriatal alpha-beta reward signaling. Key Findings 30 DBS patients participated: The sample included 14 Parkinson’s disease patients and …
TL;DR: A 2026 preprint in medRxiv analyzed plasma proteomics in Alzheimer’s disease and mild cognitive impairment and found that four continuous molecular axes described the data better than hard subtype labels. Key Findings 5,895-person AD/MCI sample: The discovery analysis used one record per participant from the Global Neurodegeneration Proteomics Consortium. 81.5% module-space variance: Four continuous …
TL;DR: A 2026 preprint in medRxiv warned that a standard Alzheimer’s disease biomarker-clock analysis can create a countdown paradox, where later biomarker-clock ages appear linked to faster mild cognitive impairment onset because of the way remaining time is calculated. Key Findings 100% false positives in simple null simulations: The standard countdown analysis rejected the null …
